24 Feb 2021 --- Lesaffre is launching an offer to acquire all outstanding shares of NattoPharma. The offer values the total equity of the Norway-based vitamin K2 expert at NOK 631 million (US$75 million) on a fully diluted basis. In an exclusive interview, Kjetil Ramsøy, NattoPharma’s CEO, speaks to NutritionInsight about what this offer means for the future of the company, including its R&D and product offerings.
